Pfizer faces significant revenue declines as key drug patents expire, but aims to maintain stable earnings through 2028 with a new drug pipeline and cost-saving measures targeting up to $4 billion in savings. The company projects 2026 revenues of $61.5 billion, minimal COVID-19 income, and expects growth to resume by 2029. Investors benefit from a 6.2% dividend yield and potential upside from recent acquisitions like Metsera, Seagen, and Biohaven.
Pfizer shares trade at USD 28.19 on Pluang as of Sep 25, 2026 03:02 WIB, showing a modest 0.93% gain in the past day. Despite the company's plans for cost-cutting and new drug development, Pluang investors currently show a strong selling bias with 99% of order activity on the platform being sell orders. The stock offers a 6.1% dividend yield, close to the 6.2% mentioned in the news, highlighting income appeal amid strategic shifts.
Eli Lilly reported a 47.7% revenue increase in Q2 2026, driven by strong sales of Mounjaro and Zepbound, and raised its full-year revenue guidance. Pfizer showed modest growth with a 5.4% revenue increase in Q1 2026, focusing on oncology and obesity ...
AT&T, Verizon, and Pfizer are three large dividend-paying stocks trading below $50, making them accessible for investors with under $1,000 per stock. Together, a $3,000 investment in these stocks could generate approximately $166.80 in annual passive...
Pfizer has been upgraded to a buy rating due to its attractive low valuation, robust free cash flow, and a high dividend yield of 6.2%. The company reported better-than-expected Q2 results and raised its full-year revenue guidance, supported by progr...
Pfizer reported a strong quarterly performance, raising its revenue guidance to $61.5 billion driven by a robust non-COVID product portfolio and recent acquisitions. The company is implementing operational efficiency programs aimed at saving $9.7 bil...
Pfizer has been downgraded from Buy to Hold following a roughly 20% total return since last October. The analyst notes that the stock's valuation, currently around 8.7 times EV/EBITDA, offers less downside protection, and near-term earnings visibilit...
